Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kyle Ford

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Scientific Reports|May 11, 2023
Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulationKyle Ford, Brenton P Munson, Samson H Fong, et al.
Nature Catalysis|December 5, 2022
Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzymeJohn Blazeck, Christos S Karamitros, Kyle Ford, et al.
Nature Biotechnology|July 17, 2018
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzymeTodd A Triplett, Kendra C Garrison, Nicholas Marshall, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Scientific Reports|May 11, 2023
Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulationKyle Ford, Brenton P Munson, Samson H Fong, et al.
Nature Catalysis|December 5, 2022
Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzymeJohn Blazeck, Christos S Karamitros, Kyle Ford, et al.
Nature Biotechnology|July 17, 2018
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzymeTodd A Triplett, Kendra C Garrison, Nicholas Marshall, et al.
Pageof 2